Sensus Healthcare (SRTS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting is scheduled for May 29, 2026, with proxy materials distributed to shareholders of record as of April 10, 2026.
Key items include election of two Class II directors, advisory approval of executive compensation, and ratification of the independent auditor.
The proxy statement is accompanied by the 2025 Annual Report, including audited financials and management's discussion.
Voting matters and shareholder proposals
Shareholders will vote on electing two Class II directors for three-year terms, a say-on-pay advisory vote, and ratification of Carr, Riggs & Ingram, LLC as auditor for 2026.
Shareholders may submit proposals for the 2027 meeting by January 1, 2027, and director nominations between January 29 and February 28, 2027.
Voting can be done online, by phone, mail, or in person at the meeting.
Board of directors and corporate governance
The board consists of six members divided into three classes, with staggered three-year terms.
Four directors are independent per Nasdaq standards; two are not independent.
Committees include Audit, Compensation, and Corporate Governance/Nominating, each with defined oversight roles.
The board held eight meetings in 2025, with high attendance.
A code of ethics and business conduct applies to all directors, officers, and employees.
Latest events from Sensus Healthcare
- Revenue dropped, but new CPT codes and recurring revenue are boosting engagement and outlook.SRTS
Q1 2026 - Reimbursement clarity and strong cash reserves set the stage for profitability in 2026.SRTS
Q4 2025 - Shareholders will vote on director election, incentive plan amendment, executive pay, and auditor ratification.SRTS
Proxy Filing - Q3 2025 revenue and profit fell, but new CMS codes and strong cash support future growth.SRTS
Q3 2025 - Q2 revenue and profit declined, but recurring revenue and FDA treatment volume increased.SRTS
Q2 2025 - Q3 2024 revenue surged 127% year-over-year, with strong sales and major agreements fueling growth.SRTS
Q3 2024 - Q2 revenue rose 104% to $9.2M, with strong SRT sales and new recurring revenue model launched.SRTS
Q2 2024 - Q1 2025 saw lower revenue and a net loss, but FDA-driven growth and strong liquidity support recovery.SRTS
Q1 2025 - Record revenue and shipments in 2024 set the stage for recurring growth via Fair Deal Agreements.SRTS
Q4 2024